TNF Blockers’ Link To Cancer In Children Is Under FDA Investigation
Executive Summary
FDA expects an investigation into the link between tumor necrosis factor blockers and lymphoma and other cancers in children will be completed in about six months
You may also be interested in...
TNF Blocker Fungal Infection: FDA Uses REMS For Relabeling, Education
FDA is using its new drug safety authority to require label changes within 30 days for all four products in the tumor necrosis factor inhibitor class
TNF Blocker Fungal Infection: FDA Uses REMS For Relabeling, Education
FDA is using its new drug safety authority to require label changes within 30 days for all four products in the tumor necrosis factor inhibitor class
Roche’s Actemra Postmarket Safety Plan May Obviate Need For REMS
Roche may have staved off the imposition of a REMS for its rheumatoid arthritis candidate Actemra by proposing a robust pharmacovigilance of its own